Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940184 | PMC |
| http://dx.doi.org/10.1016/S0140-6736(22)00280-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19). This report describes the case of a patient with a prior history of kidney transplantation who received nirmatrelvir/ritonavir. In this case, sirolimus use was successfully stopped before nirmatrelvir/ritonavir treatment, and the nirmatrelvir/ritonavir trough concentration was determined.
View Article and Find Full Text PDFCOVID-19 residual symptoms and adverse drug reactions after oral antiviral therapy in the Singapore primary care setting.
Ann Acad Med Singap
December 2024
Clinical Research Unit, National Healthcare Group Polyclinics, Singapore.
Polypharmacy or potentially inappropriate medications among older adults with COVID-19 in a secondary hospital in China and their association with mortality.
Sci Rep
January 2025
Department of Pharmacy, Shanghai Gonghui Hospital, Shanghai, People's Republic of China.
Elderly patients with multiple concomitant chronic diseases are the particularly vulnerable during the Coronavirus disease 2019 (COVID-19) epidemic, which accounts for a large number of COVID-19-related deaths. The purpose of the study was to investigate the impact of polypharmacy and potentially inappropriate medications (PIMs) on in-hospital mortality in a secondary hospital in China. A cross-sectional, retrospective study was conducted using electronic medical data collected from Shanghai Gonghui Hospital from April 2022 to June 2022.
View Article and Find Full Text PDFData mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
PLoS One
December 2024
The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety. Based on the FDA adverse event reporting system (FAERS) database, this study aims to mine the adverse reaction signals of the latest major recommended drug Nirmatrelvir/Ritonavir for the antiviral treatment of COVID-19, so as to provide a basis for safe and rational drug use.
View Article and Find Full Text PDFInvestigation of ritonavir analogs antiretroviral natural compounds against SARS-CoV-2 envelope protein.
J Biomol Struct Dyn
February 2025
Department of Physics, DDU Gorakhpur University, Gorakhpur, Uttar Pradesh, India.
Since the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China, there has been a surge in scientific research to find a permanent cure for the disease. The main challenge in effective drug discovery is the continuously mutating nature of the SARS-CoV-2 virus. Thus, we have used the I-TASSER modeling to predict the structure of the SARS-CoV-2 viral envelope protein followed by combinatorial computational assessment to predict its putative potential small molecule inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!